Giving Viagra A Run For Its Money

Watch out, Pfizer. A new kid on the block called Cialis is out to grab a slice of the sexual-dysfunction business. But Cialis, the flagship product of biotech company ICOS (ICOS), is aiming not only for part of the male market but also for the yet-to-be-served female business. In a joint venture with Eli Lilly, Cialis is now undergoing Phase III clinical trials for treating male dysfunction. ICOS has also started Cialis in Phase II studies for female sexual dysfunction.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.